Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17443005 | 0.89 | MAP2K4 (0.43) | APPKDM4E | |
| SCHEMBL5997041 | 0.86 | CDK1 (0.48) | CDK2EGFRAPP | |
| SCHEMBL5828183 | 0.86 | CCNE2 (0.52) | HSD17B10CCNE2CCNE1CDK2STAT3 | |
| SCHEMBL3304345 | 0.85 | KCNH3 (0.39) | HSD17B10CDK2EGFRKDM4E | |
| SCHEMBL3302062 | 0.85 | TMIGD3 (0.56) | LRRK2CDK5EGFRGRM4FABP4 | |
| SCHEMBL16145902 | 0.84 | LRRK2 (0.48) | HSD17B10CCNE2CCNE1CDK2STAT3 | |
| SCHEMBL16145987 | 0.84 | APP (0.53) | HSD17B10CCNE2CCNE1CDK2STAT3 | |
| SCHEMBL16146439 | 0.84 | STAT3 (0.43) | HSD17B10CCNE2CCNE1CDK2STAT3 | |
| SCHEMBL26784724 | 0.81 | CCNE2 (0.44) | CCNE2CCNE1CDK2APP | |
| SCHEMBL3302949 | 0.81 | PDE10A (0.42) | CDK2VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10519160-B2 | Imaging agents for neural flux | THE GENERAL HOSPITAL CORPORATION (US) | 2019-12-31 | — | — | US | disclosed |
| US-10519160-B2 | Imaging agents for neural flux | THE GENERAL HOSPITAL CORPORATION (US) | 2019-12-31 | — | — | US | disclosed |
| US-20180258090-A1 | IMAGING AGENTS FOR NEURAL FLUX | UNITED STATES DEPARTMENT OF ENERGY | 2018-09-13 | — | — | US | disclosed |
| WO-2016011394-A1 | IMAGING AGENTS FOR NEURAL FLUX | THE GENERAL HOSPITAL CORPORATION (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016011394-A1 | IMAGING AGENTS FOR NEURAL FLUX | THE GENERAL HOSPITAL CORPORATION (US) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519160-B2 | Imaging agents for neural flux | SLC18A2, SLC18A3, PMP22 | HSD17B10 3411/4885CCNE2 4272/4885CCNE1 3918/4885 |
| US-20180258090-A1 | IMAGING AGENTS FOR NEURAL FLUX | SLC18A2, SLC18A3, PMP22 | HSD17B10 3411/4885CCNE2 4272/4885CCNE1 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.